Staff Reports
The policy fight over newborn drug testing took another turn this month when a public webinar walked lawyers and clinicians through how to challenge toxicology evidence in pregnancy and birth cases. The event, hosted by pregnancy-justice advocates, brought together activists, a forensic adviser and clinicians who want routine or suspicion-based testing narrowed or stopped. That shift matters — because these tests are often the only things standing between a newborn and danger at home.
What the webinar argued — and who said it
The online session, titled “From the Delivery Room to the Courtroom: Evaluating and Challenging Drug Test Evidence in Pregnancy and Birth,” pushed a clear message: perinatal toxicology testing is scientifically messy, often misread, and can lead to unfair child-welfare reports. On the panel were Miriam Mack, Campaigns & Advocacy Director and Senior Legal Counsel at Movement for Family Power; Melissa Moore, Civil Systems Reform Director at the Drug Policy Alliance; Lisa Montanez, Forensic Science Policy Advisor at the Perlmutter Center for Legal Justice at Cardozo Law; and Dr. Mishka Terplan, Co‑Founder and Co‑Director of Doing Right By Birth.
Key claims made
Panelists stressed that urine and other screens can show false positives from pain meds, medical epidurals or even poppy-seed foods. They argued these tests are used more to trigger child-welfare action than to help medical care. The group outlined legal strategies to challenge how test results are ordered, interpreted and used in court and child-protection cases.
Why this debate is not just academic
Hospitals and states are already changing rules. Some systems now limit testing to “medically indicated” cases and report fewer child-welfare referrals after doing so. Supporters of narrower testing point to racial bias in who gets screened and to leading medical groups that warn against routine, unconsented testing. Opponents — and a lot of common sense — worry that rolling back testing could mean missed signs of drug exposure, more newborns sent home to dangerous situations, and preventable tragedies. Research shows tens of thousands of infants are identified and referred each year; that volume is why hospitals and courts wrangle over policy.
Follow the advocates — and the funding
This is not only a medical debate. Advocates on the panel are allied with drug‑policy groups that have long pushed for decriminalization and less punitive responses. The Drug Policy Alliance traces part of its funding history to Open Society grantmaking, which helps explain why changes in hospital policy have picked up steam in certain cities and states. Call it ideology meeting strategy: legal playbooks, clinical advisers and activist money working together to reshape how society handles pregnant people who use drugs.
Where to go from here
Parents and babies need better answers, not slogans. False positives must be reduced and tests must be interpreted carefully — no argument there. But abandoning testing as a first line of defense would be reckless. Policy must strike a balance: protect newborns, respect maternal rights, and ensure medically sound testing with clear consent and confirmatory checks. If activists want to win public trust, they should offer solutions that keep babies safe instead of telling doctors to look the other way. After all, the point of medicine is to prevent harm — not to score ideological points at a newborn’s expense.
